论文部分内容阅读
光灵在欧洲首次获准上市光动力治疗药物光灵（ｐｈｏｔｏｆｒｉｎ，ｐｏｒｆｉｍｅｒｓｏｄｉｕｍ）是由温哥华ＱＬＴ（ＱｕａｄｒａＬｏｇｉｃＴｅｃｈ－ｎｏｌｏｇｉｅｓ）公司开发的，最近获准上市，但具体上市时间尚未确定。在荷兰应用的主要适应症是：非小细胞肺癌或...
Photofluorescence Approved for the First Time in Europe Photo-Photodynamic Therapy Photofrin (porfimersodium) was developed by QuadraLogicTech in Vancouver and was recently approved for listing, but the time to market is yet to be determined. The main indications for use in the Netherlands are: non-small cell lung cancer or ...